Separate terms with OR to return results that match either term.
 
Clear All

716 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9098 Cytarabine Cytarabine Liposome 10 mg Chemotherapy Antimetabolite Pyrimidine Analog No 1999 Jan. 1, 2004 In Use
J9100 Cytarabine Cytarabine 100 mg Chemotherapy Antimetabolite Pyrimidine Analog No 1998 Jan. 1, 1986 In Use
J9110 Cytarabine Cytarabine 500 mg Chemotherapy Antimetabolite Pyrimidine Analog No 1998 Jan. 1, 1994 Dec. 31, 2010 No Longer Used
NA Dabrafenib Tafinlar 50 mg Chemotherapy Tyrosine Kinase Inhibitor BRAF Yes 2013 Jan. 1, 2004 In Use
NA Dabrafenib Tafinlar 75 mg Chemotherapy Tyrosine Kinase Inhibitor BRAF Yes 2013 Jan. 1, 2004 In Use
C9423 Dacarbazine Dacarbazine 100 mg Chemotherapy Alkylating Agent Purine Analog No 1975 Jan. 1, 2004 Dec. 31, 2005 No Longer Used
J9130 Dacarbazine Dacarbazine 100 mg Chemotherapy Alkylating Agent Purine Analog No 1975 Jan. 1, 1986 In Use
J9140 Dacarbazine Dacarbazine 200 mg Chemotherapy Alkylating Agent Purine Analog No 1975 Jan. 1, 1994 Dec. 31, 2010 No Longer Used
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
J9120 Dactinomycin Cosmegen 0.5 mg Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides No 1964 Jan. 1, 1984 In Use
C9476 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 July 1, 2016 In Use
J9415 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jan. 1, 2017 In Use
C9062 Daratumumab Hyaluronidase Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct. 1, 2020 Jan. 1, 2021 No Longer Used
J9144 Daratumumab, hyaluronidase-fihj Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Jan. 1, 2021 In Use
J0881 Darbepoetin alfa Aranesp 1 mcg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2001 Jan. 1, 2006 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Dasatinib Sprycel 50 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Dasatinib Sprycel 70 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Dasatinib Sprycel 80 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Dasatinib Sprycel 100 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Dasatinib Sprycel 140 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
C9424 Daunorubicin Daunorubicin Hydrochloride 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1996 Jan. 1, 2004 Dec. 31, 2005 No Longer Used
J9150 Daunorubicin Daunorubicin Hydrochloride 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1996 Jan. 1, 1986 In Use
J9151 Daunorubicin DaunoXome 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1996 Jan. 1, 1999 In Use

Found 716 results in 2 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.